On April 2, 2018, the Centers for Medicare & Medicaid Services (CMS) released a final rule to revise regulations and clarify program requirements within the Medicare Advantage (MA) and the Prescription Drug Benefit (Part D)...more
4/9/2018
/ Biologics ,
Biosimilars ,
Cooperative Compliance Regime ,
Final Rules ,
Generic Drugs ,
Medicare Advantage ,
Medicare Part D ,
Pharmacies ,
Rebates ,
Regulatory Oversight ,
Star Ratings ,
Uniformity
CMS released the first major MA/Part D rulemaking in several years, proposing a number of significant changes to the Part D program, including required pass-through of pharmaceutical company rebates to lower patient...more
Manufacturers of pharmaceuticals and biologics have been closely watching the industry-wide investigation by the Boston U.S. Attorney's Office into manufacturer support of independent charitable foundations that assist...more